All IndicationsPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2Phase 1
Acute Pain
3
Companies
7
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
VRTX
Vertex Pharmaceuticals Incorporated
SUZ
VRTX
Vertex Pharmaceuticals Incorporated
HB/APAP
VRTX
Vertex Pharmaceuticals Incorporated
VX-993
VRTX
Vertex Pharmaceuticals Incorporated
VX-548
Fast Track
LLY
Eli Lilly and Company
Placebo
VRTX
Vertex Pharmaceuticals Incorporated
Placebo (matched to VX-548)
XENE
Xenon Pharmaceuticals
XEN1701
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | SUZ | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | HB/APAP | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-993 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-548 | Phase 2 | FT | — | — |
| LLY Eli Lilly and Company | Placebo | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Placebo (matched to VX-548) | Phase 2 | — | — | — |
| XENE Xenon Pharmaceuticals | XEN1701 | Phase 1 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
4
Phase 1
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.